COMP <GO>
MDGL vs MRK // FORWARD P/E MULTIPLE
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MDGL 3
— MRK 11
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $430.36 (-0.31%) • MKT CAP: $9.97B
forward-pe
24.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 20.70% | -50.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | 3.42% | -5.33 | MRK | /fcf-yield <GO> |
| Operating Margin | -31.30% | 34.30% | -65.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 28.10% | -58.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 5.19 | +2.46 | MDGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.5 | 56.9 | -27.36 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.0x | 18.4x | +5.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $361.02B | -$351.05B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | MRK REV | MDGL GROSS % | MRK GROSS % | MDGL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $65.01B | 44.0% | 74.8% | -$190.0M | $12.36B |
| FY 2024 | $180.1M | $64.17B | 96.5% | 76.3% | -$457.0M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$324.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
MRK // BETA 0.92